GSK's bepirovirsen achieved a functional cure in ~20% of chronic hepatitis B patients in late-stage Phase III trials, a historically unprecedented result for a disease with ~300 million sufferers globally. The data creates a meaningful re-rating catalyst for GSK, with a partnered royalty upside for Ionis Pharmaceuticals, though the consensus is already mixed and the stock barely moved on the news.